Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
pmv.eu

See what CB Insights has to offer

Investments

140

Portfolio Exits

28

About PMV

PMV, Participatiemaatschappij Vlaanderen, is a venture capital firm financing promising companies.

PMV Headquarter Location

Oude Graanmarkt 63

Brussels, 1000,

Belgium

+32 02/229 52 30

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

PMV Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

PMV Rank

Latest PMV News

Publication of transparency notifications

Jul 15, 2021

(Article 14(1) of the Law of 2 May 2007 on the disclosure of large shareholders in issuers whose shares are admitted to trading on a regulated market) Ghent, BELGIUM – 15 July 2021, 07:00 CEST – Biotalys (Euronext - BTLS), an AgTech company focused on addressing food protection challenges to enable a more sustainable and safer food supply, announces today, in accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that it has received transparency notifications from Ackermans & van Haaren NV, Gimv NV, Adviesbeheer Gimv Venture Capital 2010 NV and Biotech Fonds Vlaanderen NV, Sofinnova Partners S.A.S., ParticipatieMaatschappij Vlaanderen NV, K&E BV, Biovest NV, Madeli participaties B.V. and Agri Investment Fund C.V.B.A. 1. Ackermans & van Haaren NV Ackermans & van Haaren NV has announced that, on 2 July 2021, it held 4,016,281 shares of Biotalys NV, representing 13.38% of the total number of voting rights. The notification dated 9 July 2021 contains the following information: Reason for the notification: holding of voting securities upon first admission to trading Notification by: a parent undertaking or a controlling person Persons subject to the notification requirement: Ackermans & van Haaren NV, Begijnenvest 113, 2000 Antwerp Stichting Administratiekantoor “Het Torentje”, Parklaan 34, 3018 BC Rotterdam (NL) Date on which the threshold was crossed: 2 July 2021 Threshold that is crossed: 10% Denominator: 30,020,387 (i) Ackermans & van Haaren NV is directly controlled by Scaldis Invest NV (ii) Scaldis Invest NV is directly controlled by Belfimas NV (iii) Belfimas NV is directly controlled by Celfloor S.A. (iv) Celfloor S.A. is directly controlled by Apodia International Holding B.V. (v) Apodia International Holding B.V. is directly controlled by Palamount S.A. (vi) Palamount S.A. is directly controlled by Stichting administratiekantoor “Het Torentje” (vii) Stichting administratiekantoor “Het Torentje” is the ultimate controlling shareholder. In accordance with article 11, §1 of the Act of 2 May 2007, stichting administratiekantoor “Het Torentje” acts in its own name and on behalf of the companies set forth under (ii) up to and including (vi). 2. Gimv NV, Adviesbeheer Gimv Venture Capital 2010 NV and Biotech Fonds Vlaanderen NV Gimv NV, Adviesbeheer Gimv Venture Capital 2010 NV and Biotech Fonds Vlaanderen have announced that, on 2 July 2021, combined they held 4,307,393 shares of Biotalys NV, representing 14.35% of the total number of voting rights. The notification dated 14 July 2021 contains the following information: Reason for the notification: holding of voting securities upon first admission to trading Notification by: % Gimv NV is not a controlled entity within the meaning of Articles 1:14 and 1:16 of the Belgian Companies and Associations Code and holds 100% of the shares in Adviesbeheer Gimv Venture Capital 2010 NV. PMV holds 100% of the shares in Biotech Fonds Vlaanderen NV, but the management of this participation has been transferred to Gimv NV. A possible divestment shall be submitted to Biotech Fonds Vlaanderen NV, but if this meets certain pre-defined criteria the necessary mandates shall be provided. By consequence, persons are acting in concert. 3. Sofinnova Partners S.A.S. Sofinnova Partners S.A.S. has announced that, on 2 July 2021, it held 4,226,962 shares of Biotalys NV, representing 14.08% of the total number of voting rights. The notification dated 9 July 2021 contains the following information: Reason for the notification: holding of voting securities upon first admission to trading Notification by: a person that notifies alone Persons subject to the notification requirement: Sofinnova Partners S.A.S., 7-11 Boulevard Haussmann - 75009 - Paris (France) Date on which the threshold was crossed: 2 July 2021 Threshold that is crossed: 10% Denominator: 30,020,387 % Sofinnova Partners S.A.S. is not a controlled entity within the meaning of Articles 1:14 and 1:16 of the Belgian Companies and Associations Code. Sofinnova Partners S.A.S. is the management company of Sofinnova Industrial Biotech I (a professional capital investment fund under French law) qualifying as collective investment undertaking in the meaning of article 9 § 2 of the royal decree of 14 February 2007, and exercises the voting rights attached to shares owned by Sofinnova Industrial Biotech at its own discretion without any instructions from the fund. 4. ParticipatieMaatschappij Vlaanderen NV ParticipatieMaatschappij Vlaanderen NV has announced that, on 2 July 2021, it held 2,494,813 shares of Biotalys NV, representing 8.31% of the total number of voting rights. The notification dated 14 July 2021 contains the following information: Reason for the notification: holding of voting securities upon first admission to trading Notification by: a parent undertaking or a controlling person Persons subject to the notification requirement: Vlaamse Gewest (Flemish Region), Martelaarsplein 19, 1000 Brussels ParticipatieMaatschappij Vlaanderen NV, Oude Graanmarkt 63, 1000 Brussels Date on which the threshold was crossed: 2 July 2021 Threshold that is crossed: 5% Denominator: 30,020,387 % The Flemish Region (het Vlaamse Gewest) holds 100% of the shares in ParticipatieMaatschappij Vlaanderen NV (PMV NV). PMV NV holds 100% of the shares in Biotech Fonds Vlaanderen NV which on its turen holds 8,31 % of the shares in Biotalys. This participation however is managed by Gimv NV. A possible divestment shall be submitted to Biotech Fonds Vlaanderen NV, but if this meets certain pre-defined criteria the necessary mandates shall be provided. 5. K&E BV K&E BV has announced that, on 2 July 2021, it held 1,867,837 shares of Biotalys NV, representing 6.22% of the total number of voting rights. The notification dated 14 July 2021 contains the following information: Reason for the notification: holding of voting securities upon first admission to trading Notification by: a parent undertaking or a controlling person Persons subject to the notification requirement: Koen Quaghebeur % Biovest NV is 100% owned by RMM SA, which is ultimately owned by Sniper Invest SA (ultimately owned by Stefan Mariën), Fontana Invest SA (ultimately owned by Frederic Mariën), and Radium Invest SA (ultimately owned by Robin Devos), each for one third. 7. Madeli participaties B.V. Madeli participaties B.V. has announced that, on 2 July 2021, it held 1,948,798 shares of Biotalys NV, representing 6.49% of the total number of voting rights. The notification dated 12 July 2021 contains the following information: Reason for the notification: holding of voting securities upon first admission to trading Notification by: a parent undertaking or a controlling person Persons subject to the notification requirement: Madeli Participaties BV, Leeuwenhoekweg 46, 2661 CZ Bergschenhoek (NL) Fran-I BV, Leeuwenhoekweg 46, 2661 CZ Bergschenhoek (NL) BBG-II BV, Leeuwenhoekweg 46, 2661 CZ Bergschenhoek (NL) Ermati-III BV, Leeuwenhoekweg 46, 2661 CZ Bergschenhoek (NL) Maurits de Ruiter % Madeli Participaties BV is controlled by Madeli BV. The latter company is controlled for 33.33% each by the following entities: Fran-I BV (controlled by Maurits de Ruiter), BBG-II BV (controlled by Wouter de Ruiter) en Ermati-III BV (controlled by Henk de Ruiter). 8. Agri Investment Fund C.V.B.A Agri Investment Fund C.V.B.A. has announced that, on 2 July 2021, it held 2,158,708 shares of Biotalys NV, representing 7.19% of the total number of voting rights. The notification dated 8 July 2021 contains the following information: Reason for the notification: holding of voting securities upon first admission to trading Notification by: a parent undertaking or a controlling person Persons subject to the notification requirement: HBB V.Z.W., Diestsevest 40, 3000 Leuven BB-Patrim C.V.B.A., Diestsevest 40, 3000 Leuven M.R.B.B. C.V.B.A., Diestsevest 32 5b, 3000 Leuven Agri Investment Fund C.V.B.A., Diestsevest 32 5b, 3000 Leuven Date on which the threshold was crossed: 2 July 2021 Threshold that is crossed: 5% Denominator: 30,020,387 BB-Patrim C.V.B.A. holds 53.5% in M.R.B.B. C.V.B.A. M.R.B.B. C.V.B.A. holds 100% in Agri Investment Fund C.V.B.A. The respective transparency notifications can be found on www.biotalys.com/investors . About Biotalys Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys has developed a strong and diverse pipeline of effective products with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and was listed on Euronext Brussels on 2 July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com . For further information, please contact Toon Musschoot, Strategic Communications Manager T: +32 (0)9 274 54 00

PMV Investments

140 Investments

PMV has made 140 investments. Their latest investment was in LynxCare as part of their Series A on June 6, 2022.

CBI Logo

PMV Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/23/2022

Series A

LynxCare

$21.05M

No

1

6/14/2022

Series A

Waylay

No

2

5/23/2022

Seed VC

Metamaze

$0.75M

Yes

1

5/10/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/5/2022

Loan

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/23/2022

6/14/2022

5/23/2022

5/10/2022

5/5/2022

Round

Series A

Series A

Seed VC

Series A

Loan

Company

LynxCare

Waylay

Metamaze

Subscribe to see more

Subscribe to see more

Amount

$21.05M

$0.75M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

10

PMV Portfolio Exits

28 Portfolio Exits

PMV has 28 portfolio exits. Their latest portfolio exit was Teamleader on June 23, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/23/2022

Acquired

$99M

2

5/31/2022

Acquired

$99M

1

1/13/2022

Acquired

$99M

3

12/14/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

11/1/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/23/2022

5/31/2022

1/13/2022

12/14/2021

11/1/2021

Exit

Acquired

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

1

3

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.